Cargando…

CTS Trials Network: A paradigm shift in the surgical treatment of moderate ischemic mitral regurgitation?

The Cardiothoracic Surgery Trials Network has reported results of the one-year follow up of their randomized trial “Surgical Treatment of Moderate Ischemic Mitral Regurgitation”. They studied 301 patients with moderate ischemic mitral regurgitation (IMR) undergoing coronary artery bypass grafting (C...

Descripción completa

Detalles Bibliográficos
Autor principal:	Afifi, Ahmed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2015
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633578/ https://www.ncbi.nlm.nih.gov/pubmed/26779511 http://dx.doi.org/10.5339/gcsp.2015.30

Ejemplares similares

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

The RIME trial: Are we closer to the answer of when to repair ischemic mitral regurgitation?
por: Afifi, Ahmed, et al.
Publicado: (2013)

CTS trials network: Rate control vs rhythm control for atrial fibrillation after cardiac surgery - Do bitter pills have blessed effects?
por: Afifi, Ahmed
Publicado: (2016)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

Radial artery as a second conduit gains momentum: The RAPCO trial
por: Simry, Walid, et al.
Publicado: (2021)

Transfusion Indication Threshold Reduction (TITRe2) trial: When to transfuse and what to give?
por: Afifi, Ahmed, et al.
Publicado: (2015)

PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?
por: Bonow, Robert O., et al.
Publicado: (2014)

PCI versus CABG in patients with complex coronary artery disease: Time for reconciliation?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE
por: Raynaud, Christophe M., et al.
Publicado: (2013)

COMPARE and Pediatric Heart Network Investigator trials: Losartan finally validated in humans with Marfan, but much work remains!
por: Yacoub, Magdi, et al.
Publicado: (2014)

Overview of trials from AHA 2021
por: Gergis, Michael, et al.
Publicado: (2021)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
por: Wagdy, Kerolos, et al.
Publicado: (2020)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
por: Suwaidi, Jassim Al
Publicado: (2016)

The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?
por: Bouhout, Ismail, et al.
Publicado: (2019)

TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014)

PLATFORM at 90 days: Evaluating the clinical utility of FFRCT
por: Kharabish, Ahmed, et al.
Publicado: (2016)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI
por: Hassan, Ahmed, et al.
Publicado: (2015)

PARIS: A good start for exercise in HFPEF
por: Elamragy, Ahmed A.
Publicado: (2014)

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
por: ElGuindy, Ahmed
Publicado: (2016)

CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
por: Yacoub, Magdi H, et al.
Publicado: (2013)

Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy
por: Kotit, Susy
Publicado: (2023)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

STREAM and FAST-MI – Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI era
por: ElGuindy, Ahmed M.
Publicado: (2014)

STREAM at one year: Further evidence supporting a pharmacoinvasive strategy in patients with STEMI
por: ElGuindy, Ahmed M.
Publicado: (2015)

FAME 2: Reshaping the approach to patients with stable coronary artery disease
por: ElGuindy, Ahmed M.
Publicado: (2015)

Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials
por: Hassan, Mohamed
Publicado: (2014)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2014)

TASTE: One-year follow-up results
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2015)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_otcbd6hllhcuhucqbh9qbq5c6h